reduc
unnecessari
antibiot
use
improv
outcom
develop
facilityspecif
guidelin
fever
neutropenia
hematooncolog
patient
center
tertiari
care
hospit
use
cefepim
initi
empir
antibiot
hematooncolog
patient
febril
neutropenia
accord
infecti
diseas
societi
empir
antibiot
escal
group
carbapenem
highrisk
patient
remain
hemodynam
unstabl
despit
initi
howev
approach
rais
concern
carbapenem
overus
implement
carbapenemsav
strategi
use
empir
combin
piperacillintazobactam
amikacin
ptzamk
bridg
regimen
use
evalu
effect
strategi
review
antibiot
use
antimicrobi
resist
overal
mortal
strategi
implement
strategi
base
vitro
data
show
ptzamk
combin
cover
extend
spectrum
escherichia
coli
sinc
aminoglycosid
rare
use
hospit
amikacin
suscept
also
rel
well
preserv
clinic
isol
pseudomona
acinetobact
spp
recommend
empir
administr
ptzamk
highrisk
hematooncolog
patient
febril
remain
hemodynam
unstabl
hour
despit
initi
cefepim
treatment
identif
pathogen
organ
strategi
recommend
consult
resid
educ
without
compulsori
protocol
although
carbapenemsav
strategi
appli
patient
febril
neutropenia
effect
amount
prescrib
antibiot
resist
pathogen
evalu
overal
hematooncolog
patient
follow
reason
antibiot
use
febril
neutropenia
would
affect
patient
flora
influenc
antimicrobi
resist
follow
infect
recoveri
neutropenia
hematooncolog
patient
admit
almost
exclus
hematooncolog
ward
resist
pathogen
could
share
patient
environ
studi
period
second
quarter
first
quarter
sinc
hospit
experienc
outbreak
middl
east
respiratori
syndrom
partial
close
second
quarter
evalu
twoyear
period
carbapenemsav
strategi
implement
first
quarter
collect
administr
mortal
antibiot
prescript
blood
cultur
data
hematooncolog
patient
hematooncolog
ward
includ
four
gener
ward
one
reverseisol
ward
bonemarrow
transplant
one
intens
care
unit
prescript
data
amk
ptz
group
carbapenem
ertapenem
imipenemcilastatin
meropenem
doripenem
calcul
day
therapi
per
personday
pd
blood
isol
enterobacteriacea
pseudomona
spp
acinetobact
spp
identifi
resist
calcul
resist
rate
per
pd
blood
cultur
taken
peripher
vein
central
line
process
bactalert
system
inc
marci
letoil
franc
speci
identif
antimicrobi
suscept
test
vitek
ii
autom
system
inc
use
util
standard
identif
card
modifi
broth
microdilut
method
minimum
inhibitori
concentr
breakpoint
qualitycontrol
protocol
use
accord
standard
establish
clinic
laboratori
standard
institut
ptz
suscept
acinetobact
spp
report
student
ttest
use
comparison
continu
variabl
evalu
associ
antibiot
prescript
resist
monthli
antibiot
resist
rate
compar
averag
dot
prior
three
month
use
linear
regress
model
p
valu
twotail
p
consid
statist
signific
ibm
spss
statist
version
ibm
corp
armonk
ny
usa
use
studi
approv
institut
review
board
irb
samsung
medic
center
irb
inform
consent
waiv
sinc
overal
statist
data
use
without
review
medic
record
individu
patient
studi
period
total
patient
admit
hematooncolog
ward
averag
pd
monthli
patient
differ
strategi
implement
p
tabl
allcaus
mortal
differ
two
period
death
per
pd
p
monthli
dot
amk
ptz
significantli
increas
strategi
implement
amk
p
ptz
p
increment
ptz
use
far
exceed
amk
ptz
use
increas
monthli
dot
strategi
implement
amk
increas
dot
monthli
dot
significantli
decreas
strategi
implement
p
use
chang
incid
gramneg
bacteremia
significantli
chang
enterobacteriacea
frequent
isol
averag
monthli
case
per
pd
follow
pseudomona
spp
acinetobact
spp
overal
trend
antibiot
resist
present
fig
associ
antibiot
prescript
resist
fig
strategi
implement
antibiot
resist
rate
enterobacteriacea
averag
per
pd
amk
ptz
ptz
resist
significantli
increas
strategi
implement
per
pd
p
tabl
amk
resist
increas
studi
period
despit
increas
amk
prescript
fig
relationship
amk
prescript
resist
observ
fig
increas
use
ptz
increas
ptz
resist
seen
studi
period
p
proport
increas
ptz
resist
accord
ptz
prescript
observ
p
although
carbapenem
prescript
significantli
decreas
signific
reduct
carbapenem
resist
observ
relationship
seen
carbapenem
prescript
resist
antibiot
resist
pseudomona
spp
averag
per
pd
amk
ptz
strategi
implement
resist
chang
implement
tabl
overal
trend
antibiot
resist
pseudomona
spp
fig
associ
antibiot
prescript
resist
fig
relationship
observ
antibiot
prescript
resist
antibiot
resist
acinetobact
spp
averag
per
pd
amk
strategi
implement
carbapenem
resist
rate
significantli
increas
implement
p
tabl
overal
trend
antibiot
resist
acinetobact
spp
fig
associ
antibiot
prescript
resist
fig
although
carbapenem
resist
increas
strategi
implement
associ
prior
prescript
p
addit
system
antibiot
stewardship
program
use
computer
clinic
decis
support
emphas
noncompulsori
method
educ
lectur
confer
consult
evalu
carbapenemsav
strategi
repres
effect
method
increas
amk
prescript
strategi
implement
substitut
overal
use
decreas
significantli
allcaus
mortal
use
chang
strategi
implement
good
complianc
noncompulsori
strategi
owe
prescrib
understand
concern
antibiot
resist
howev
increas
ptz
prescript
directli
relat
carbapenemsav
strategi
led
increas
ptz
resist
enterobacteriacea
although
think
main
deriv
forc
ptz
overus
would
increas
incid
drugresist
gramneg
pathogen
rel
preserv
ptz
carbapenemsav
strategi
might
contribut
ptz
overus
indic
weaken
psycholog
barrier
ptz
prescript
suggest
implement
antibioticus
strategi
accompani
care
monitor
overal
antibiot
use
direct
impact
decreas
carbapenem
prescript
limit
prevent
increas
carbapenem
resist
carbapenemresist
enterobacteriacea
rare
identifi
strategi
implement
carbapenemresist
nonferment
pseudomona
acinetobact
spp
show
meaning
chang
studi
period
relationship
antibiot
prescript
resist
observ
nonferment
probabl
could
adjust
resist
factor
includ
environment
contamin
transmiss
longterm
care
also
sinc
data
evalu
overal
use
antibiot
resist
rate
perpati
relationship
antibiot
use
resist
evalu
conclus
carbapenemsav
strategi
use
ptzamk
bridg
regimen
patient
febril
neutropenia
effect
suppress
overal
carbapenem
use
hematooncolog
ward
type
bridg
regimen
may
appli
hospit
base
local
epidemiolog
data
along
overal
antibiot
usag
monitor
